Rational design of potent sialidase-based inhibitors of influenza virus replication

von Itzstein, Mark, Wu, Wen-Yang, Kok, Gaik B., Pegg, Michael S., Dyason, Jeffrey C., Jin, Betty, Van Phan, Tho, Smythe, Mark L. +10 more·1993·Nature
DOI 10.1038/363418a0

Cited by (1,001)

Items 101–200 of 1,001

  1. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B
    D Turner, Allan Wailoo, K. G. Nicholson, Nicola J. Cooper, Alex J. Sutton, Keith R. Abrams · 2003 · Health Technology Assessment
  2. Occurrence of a sialylglycopeptide and free sialylglycans in hen's egg yolk
    Akira Seko, Mamoru Koketsu, Masakazu Nishizono, Yuko Enoki, Hisham Radwan Ibrahim, Lekh Raj Juneja, Mujo Kim, Takehiko Yamamoto · 1997 · Biochimica et Biophysica Acta (BBA) - General Subjects
  3. Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses
    Elena A. Govorkova, Ирина Анатольевна Ленева, Olga G. Goloubeva, Karen Bush, Robert G. Webster · 2001 · Antimicrobial Agents and Chemotherapy
  4. Enzymes in Organic Synthesis: Application to the Problems of Carbohydrate Recognition (Part 2)
    Chi‐Huey Wong, Randall L. Halcomb, Yoshitaka Ichikawa, Tetsuya Kajimoto · 1995 · Angewandte Chemie International Edition in English
  5. The Hemagglutinin-Neuraminidase Protein of Newcastle Disease Virus Determines Tropism and Virulence
    Zhuhui Huang, Aruna Panda, Subbiah Elankumaran, Dhanasekaran Govindarajan, Daniel D. Rockemann, Siba K. Samal · 2004 · Journal of Virology
  6. Docking Validation Resources: Protein Family and Ligand Flexibility Experiments
    Sudipto Mukherjee, Trent E. Balius, Robert C. Rizzo · 2010 · Journal of Chemical Information and Modeling
  7. Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors
    JOHN S. OXFORD, S. Bossuyt, Shobana Balasingam, Anita Mann, Patricia Novelli, Rob Lambkin‐Williams · 2003 · Clinical Microbiology and Infection
  8. Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
    Jason E. Hudak, Carolyn Ruth Bertozzi · 2013 · Chemistry & Biology
  9. Crystal structure of a bacterial sialidase (from Salmonella typhimurium LT2) shows the same fold as an influenza virus neuraminidase.
    Crennell, S J, Garman, E F, Laver, W G, Vimr, E R, Taylor, G L · 1993 · Proceedings of the National Academy of Sciences
  10. Pharmacokinetics of Zanamivir After Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers
    Lindsey Cass, Constantin Efthymiopoulos, Alan Bye · 1999 · Clinical Pharmacokinetics
  11. Computational approaches to identifying and characterizing protein binding sites for ligand design
    Stefan Henrich, Outi M. H. Salo‐Ahen, Bingding Huang, Friedrich Rippmann, Gabriele Cruciani, Rebecca C. Wade · 2009 · Journal of Molecular Recognition
  12. The GD1a glycan is a cellular receptor for adenoviruses causing epidemic keratoconjunctivitis
    Emma Nilsson, Rickard Storm, Johannes Bauer, Susanne Johansson, Aivar Lõokene, Jonas Ångström, Mattias Hedenström, Thérèse Eriksson, Lars Frängsmyr, Simon Rinaldi et al. · 2010 · Nature Medicine
  13. Biochemistry and Role of Sialic Acids
    Roland Schauer, Sørge Kelm, Gerd Reuter, Peter Roggentin, Lee Shaw · 1995 · Springer eBooks
  14. Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071
    Weixing Li, Paul A. Escarpe, Eugene J. Eisenberg, Kenneth C. Cundy, Clive Sweet, K. J. Jakeman, James R. Merson, Willard Lew, M.A. Williams, Lijun Zhang et al. · 1998 · Antimicrobial Agents and Chemotherapy
  15. Sialidases: structures, biological significance and therapeutic potential
    Garry L. Taylor · 1996 · Current Opinion in Structural Biology
  16. The Significance of G Protein-Coupled Receptor Crystallography for Drug Discovery
    John A. Salon, David T. Lodowski, Krzysztof Palczewski · 2011 · Pharmacological Reviews
  17. Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology
    JOHN S. OXFORD · 2000 · Reviews in Medical Virology
  18. Chemistry, biochemistry and biology of sialic acids
    Roland Schauer, Johannis P. Kamerling · 1997 · New comprehensive biochemistry
  19. Synthetic Approaches to the Neuraminidase Inhibitors Zanamivir (Relenza) and Oseltamivir Phosphate (Tamiflu) for the Treatment of Influenza
    Javier Magano · 2009 · Chemical Reviews
  20. The three domains of a bacterial sialidase: a β-propeller, an immunoglobulin module and a galactose-binding jelly-roll
    Andrew Gaskell, S.J. Crennell, Garry L. Taylor · 1995 · Structure
  21. Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors
    Vasiliy P. Mishin, Frederick G. Hayden, Larisa V. Gubareva · 2005 · Antimicrobial Agents and Chemotherapy
  22. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2
    Richard W. Schevitz, Nicholas J. Bach, D. G. CARLSON, Nickolay Y. Chirgadze, David K. Clawson, Robert D. Dillard, Susan E. Draheim, Lawrence W. Hartley, N.D. Jones, Edward D. Mihelich et al. · 1995 · Nature Structural & Molecular Biology
  23. Disulfide‐Reductase Inhibitors as Chemotherapeutic Agents: The Design of Drugs for Trypanosomiasis and Malaria
    R. Heiner Schirmer, Joachim G. Müller, R. Luise Krauth‐Siegel · 1995 · Angewandte Chemie International Edition in English
  24. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en
    Larisa V. Gubareva, Megan J. Robinson, Richard C. Bethell, Robert G. Webster · 1997 · Journal of Virology
  25. Nasal Cytokine and Chemokine Responses in Experimental Influenza A Virus Infection: Results of a Placebo‐Controlled Trial of Intravenous Zanamivir Treatment
    R. Scott Fritz, Frederick G. Hayden, David P. Calfee, Lindsey Cass, Amy Peng, W. Gregory Alvord, Warren Strober, Stephen E. Straus · 1999 · The Journal of Infectious Diseases
  26. Evaluation of Neuraminidase Enzyme Assays Using Different Substrates To Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network
    Neal T. Wetherall, Toral Trivedi, J. Zeller, Cheryl A. Hodges-Savola, Jennifer L. McKimm‐Breschkin, Maria Cristina Fleischmann Alves Zambon, Frederick G. Hayden · 2003 · Journal of Clinical Microbiology
  27. Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19
    Atanu Acharya, Rupesh Agarwal, Matthew B. Baker, Jerome Y. Baudry, Debsindhu Bhowmik, Stephanie Boehm, Kendall Byler, Sirui Chen, Leighton Coates, Connor J. Cooper et al. · 2020 · Journal of Chemical Information and Modeling
  28. Enzyme action in glycoprotein synthesis
    P.S. Sears, Chi‐Huey Wong · 1998 · Cellular and Molecular Life Sciences
  29. Crystal structure of Vibrio cholerae neuraminidase reveals dual lectin-like domains in addition to the catalytic domain
    Crennell, Susan, Garman, Elspeth, Laver, Graeme, Vimr, Eric, Taylor, Garry · 1994 · Structure
  30. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro
    Guus F. Rimmelzwaan, Marianne M. J. W. Baars, Eric C. J. Claas, Albert D. M. E. Osterhaus · 1998 · Journal of Virological Methods
  31. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en
    Larisa V. Gubareva, Richard C. Bethell, G J Hart, K. Gopal Murti, Charles R. Penn, Robert G. Webster · 1996 · Journal of Virology
  32. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase
    Joseph N Varghese, Paul W. Smith, Steven L. Sollis, Tony Blick, Anjali Sahasrabudhe, Jennifer L. McKimm‐Breschkin, Peter M. Colman · 1998 · Structure
  33. Virtual screening using molecular simulations
    Tianyi Yang, Johnny C. Wu, Chunli Yan, Yuanfeng Wang, Ray Luo, Michael B. Gonzales, Kevin N. Dalby, Pengyu Y. Ren · 2011 · Proteins Structure Function and Bioinformatics
  34. New roles for structure in biology and drug discovery.
    Robert B. Russell, Drake S. Eggleston · 2000 · Nature Structural Biology
  35. Synthesis of Tamiflu and its Phosphonate Congeners Possessing Potent Anti-Influenza Activity
    Jiun‐Jie Shie, Jim‐Min Fang, Shiyun Wang, Keng‐Chang Tsai, Yih‐Shyun E. Cheng, An‐Suei Yang, Shih-Chia Hsiao, Ching‐Yao Su, Chi‐Huey Wong · 2007 · Journal of the American Chemical Society
  36. Three‐dimensional structure of the complex of 4‐guanidino‐Neu5Ac2en and influenza virus neuraminidase
    Joseph N Varghese, V. Chandana Epa, Peter M. Colman · 1995 · Protein Science
  37. Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity
    Jin‐Hyo Kim, Ricardo Resende, Tom Wennekes, Hongming Chen, Nicole Bance, Sabrina Buchini, Andrew G. Watts, Patricia A. Pilling, Victor A. Streltsov, Martin Petric et al. · 2013 · Science
  38. Recent Advances in the Synthesis of Sialic Acid Derivatives and Sialylmimetics as Biological Probes
    Milton J. Kiefel, Mark von Itzstein · 2002 · Chemical Reviews
  39. Beyond Picomolar Affinities: Quantitative Aspects of Noncovalent and Covalent Binding of Drugs to Proteins
    Smith, Adam J. T., Zhang, Xiyun, Leach, Andrew G., Houk, K. N. · 2009 · Journal of Medicinal Chemistry
  40. Dihydropyrancarboxamides Related to Zanamivir: A New Series of Inhibitors of Influenza Virus Sialidases. 2. Crystallographic and Molecular Modeling Study of Complexes of 4-Amino-4H-pyran-6-carboxamides and Sialidase from Influenza Virus Types A and B
    Neil R. Taylor, Anne Cleasby, Onkar Singh, Tadeusz J. Skarzynski, Alan J. Wonacott, Paul W. Smith, Steven L. Sollis, Peter D. Howes, Peter C. Cherry, Richard C. Bethell et al. · 1998 · Journal of Medicinal Chemistry
  41. Prevention and Treatment of Influenza
    Robert B. Couch · 2000 · New England Journal of Medicine
  42. Biocatalysis: Synthesis of Key Intermediates for Development of Pharmaceuticals
    Ramesh N. Patel · 2011 · ACS Catalysis
  43. Antiviral strategies against influenza virus: towards new therapeutic approaches
    Arianna Loregian, Beatrice Mercorelli, Giulio Nannetti, Chiara Compagnin, Giorgio Palù · 2014 · Cellular and Molecular Life Sciences
  44. Importance of Neuraminidase Active-Site Residues to the Neuraminidase Inhibitor Resistance of Influenza Viruses
    Hui‐Ling Yen, Erich Hoffmann, Garry L. Taylor, Christoph Scholtissek, Arnold S. Monto, Robert G. Webster, Elena A. Govorkova · 2006 · Journal of Virology
  45. Drug permeation in biomembranes
    Annika Mälkiä, Lasse S. Murtomäki, Arto O. Urtti, Kyösti Kontturi · 2004 · European Journal of Pharmaceutical Sciences
  46. Discovery of intramolecular trans-sialidases in human gut microbiota suggests novel mechanisms of mucosal adaptation
    Tailford, Louise E., Owen, C. David, Walshaw, John, Crost, Emmanuelle H., Hardy-Goddard, Jemma, Le Gall, Gwenaelle, de Vos, Willem M., Taylor, Garry L., Juge, Nathalie · 2015 · Nature Communications
  47. Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors
    Jennifer L. McKimm‐Breschkin, Anjali Sahasrabudhe, Tony Blick, Mandy McDonald, Peter M. Colman, Graham J. Hart, Richard C. Bethell, Joseph N Varghese · 1998 · Journal of Virology
  48. Genetics of Influenza Viruses
    David A. Steinhauer, John James Skehel · 2002 · Annual Review of Genetics
  49. Clinical Efficacy and Safety of the Orally Inhaled Neuraminidase Inhibitor Zanamivir in the Treatment of Influenza: a Randomized, Double-blind, Placebo-controlled European Study
    Mika Juhani Mäkelä, Karlis Pauksens, Timo Rostila, Douglas Fleming, Choy Y. Man, Oliver N. Keene, Alison Webster · 2000 · Journal of Infection
  50. A Novel Approach for Predicting P-Glycoprotein (ABCB1) Inhibition Using Molecular Interaction Fields
    Fabio Broccatelli, Emanuele Carosati, Annalisa Neri, Maria Frosini, Laura Goracci, Tudor Ionel Oprea, Gabriele Cruciani · 2011 · Journal of Medicinal Chemistry
  51. Systematic Structure-Based Design and Stereoselective Synthesis of Novel Multisubstituted Cyclopentane Derivatives with Potent Antiinfluenza Activity
    Pooran Chand, Pravin L. Kotian, Ali Dehghani, Yahya A. El-Kattan, Tsu‐Hsing Lin, Tracy L. Hutchison, Yarlagadda S. Babu, Shanta Bantia, Arthur J. Elliott, John A. Jr. Montgomery · 2001 · Journal of Medicinal Chemistry
  52. Structural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition
    Christopher John Vavricka, Qing Li, Yan Wu, Jianxun Qi, Mingyang Wang, Yue Liu, Feng Gao, Jun Liu, Enguang Feng, Jianhua He et al. · 2011 · PLoS Pathogens
  53. Limited Inhibitory Effects of Oseltamivir and Zanamivir on Human Sialidases
    Keiko Hata, Koichi Koseki, Kazunori Yamaguchi, Setsuko Moriya, Yasuo Suzuki, Sangchai Yingsakmongkon, Go Hirai, Mikiko Sodeoka, Mark von Itzstein, Taeko Miyagi · 2008 · Antimicrobial Agents and Chemotherapy
  54. Diagnosis of Influenza in the Community
    Maria Cristina Fleischmann Alves Zambon, John Philip Hays, Alison Webster, Robert W. Newman, Oliver N. Keene · 2001 · Archives of Internal Medicine
  55. Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children
    Iain Stephenson, Jane Democratis, Angie Lackenby, Teresa McNally, James Smith, Manish Pareek, Joanna Ellis, Alison Bermingham, Karl G. Nicholson, Maria Cristina Fleischmann Alves Zambon · 2009 · Clinical Infectious Diseases
  56. Antiviral Approaches against Influenza Virus
    Rashmi Kumari, Suresh D. Sharma, Amrita Kumar, Zachary S. Ende, Margarita Mishina, Yuanyuan Wang, Zackary Falls, Ram Samudrala, Jan Pohl, Paul R. Knight et al. · 2023 · Clinical Microbiology Reviews
  57. Meaning and therapeutic potential of microbial recognition of host glycoconjugates
    Karl‐Anders Karlsson · 1998 · Molecular Microbiology
  58. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor
    Robert W. Sidwell, John H. Huffman, Dale L. Barnard, Kevin W. Bailey, Min‐Hui Wong, Ann C. Morrison, Timothy Syndergaard, Choung U. Kim · 1998 · Antiviral Research
  59. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance
    Olivier Ferraris, Bruno Lina · 2007 · Journal of Clinical Virology
  60. Cyclopentane Neuraminidase Inhibitors with Potent In Vitro Anti-Influenza Virus Activities
    Donald F. Smee, John H. Huffman, Ann C. Morrison, Dale L. Barnard, Robert W. Sidwell · 2001 · Antimicrobial Agents and Chemotherapy
  61. Influenza Virus Neuraminidase: Structure and Function
    Ю А Штыря, Larisa V. Mochalova, Nicolai Vladimirovich Bovin · 2009 · Acta Naturae
  62. Biocatalysis for synthesis of pharmaceuticals
    Ramesh N. Patel · 2017 · Bioorganic & Medicinal Chemistry
  63. Biosynthetic Modulation of Sialic Acid-dependent Virus-Receptor Interactions of Two Primate Polyoma Viruses
    Oliver T. Keppler, Peer Stehling, Markus Herrmann, Holger Kayser, Detlef Grunow, Werner G. Reutter, Michael Pawlita · 1995 · Journal of Biological Chemistry
  64. In the Shadow of Hemagglutinin: A Growing Interest in Influenza Viral Neuraminidase and Its Role as a Vaccine Antigen
    Teddy John Wohlbold, Florian Krammer · 2014 · Viruses
  65. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses
    Ирина Анатольевна Ленева, Noel A. Roberts, Elena A. Govorkova, Olga G. Goloubeva, Robert G. Webster · 2000 · Antiviral Research
  66. Analysis of PUGNAc and NAG-thiazoline as Transition State Analogues for Human O-GlcNAcase: Mechanistic and Structural Insights into Inhibitor Selectivity and Transition State Poise
    Garrett E. Whitworth, Matthew Scott Macauley, Keith A. Stubbs, Rebecca J. Dennis, Edward J. Taylor, G.J. Davies, Ian R. Greig, David J. Vocadlo · 2006 · Journal of the American Chemical Society
  67. Biological activities of guanidine compounds
    Franciszek Sa̧czewski, Łukasz Balewski · 2009 · Expert Opinion on Therapeutic Patents
  68. Asymmetrische Aktivierung
    Köichi Mikami, Masahiro Terada, Toshinobu Korenaga, Yousuke Matsumoto, Makoto Ueki, Rémy Angelaud · 2000 · Angewandte Chemie
  69. Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo
    Hui‐Ling Yen, Natalia A. Ilyushina, Rachelle Salomon, Erich Hoffmann, Robert G. Webster, Elena A. Govorkova · 2007 · Journal of Virology
  70. Influenza neuraminidase: A druggable target for natural products
    Ulrike Grienke, Michaela Schmidtke, Susanne von Grafenstein, Johannes Kirchmair, Klaus Roman Liedl, Judith Maria Rollinger · 2011 · Natural Product Reports
  71. Towards accurate free energy calculations in ligand protein-binding studies.
    T. Steinbrecher, A. Labahn · 2010 · Current Medicinal Chemistry
  72. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants
    Natalia A. Ilyushina, Nicolai Vladimirovich Bovin, Robert G. Webster, Elena A. Govorkova · 2006 · Antiviral Research
  73. Discovery of Pentacyclic Triterpenoids as Potential Entry Inhibitors of Influenza Viruses
    Maorong Yu, Longlong Si, Yufei Wang, Yiming Wu, Fei Yu, Pingxuan Jiao, Yongying Shi, Han Wang, Sulong Xiao, Ge Fu et al. · 2014 · Journal of Medicinal Chemistry
  74. The pH of Activation of the Hemagglutinin Protein Regulates H5N1 Influenza Virus Pathogenicity and Transmissibility in Ducks
    Mark L. Reed, Olga A. Bridges, Patrick Seiler, Jeong-Ki Kim, Hui‐Ling Yen, Rachelle Salomon, Elena A. Govorkova, Robert G. Webster, Charles J. Russell · 2009 · Journal of Virology
  75. Influenza B virus neuraminidase can synthesize its own inhibitor
    Wim Pascal Burmeister, Bernard Henrissat, C. Bosso, S. Cusack, Rob W. H. Ruigrok · 1993 · Structure
  76. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis
    Arnold S. Monto, A. Webster, Oliver N. Keene · 1999 · Journal of Antimicrobial Chemotherapy
  77. Outcome of a Workshop on Applications of Protein Models in Biomedical Research
    Torsten F. Schwede, Andrej Šali, Barry H. Honig, Michael Levitt, Helen Miriam Berman, David T. Jones, Steven E. Brenner, Stephen Kevin Burley, Rhiju Das, Nikolay V. Dokholyan et al. · 2009 · Structure
  78. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en
    Jennifer L. McKimm‐Breschkin, Tony Blick, Anjali Sahasrabudhe, Tak S. Tiong, D Marshall, G J Hart, Richard C. Bethell, Charles R. Penn · 1996 · Antimicrobial Agents and Chemotherapy
  79. Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir
    Shanta Bantia, Cynthia Davis Parker, Sandya L. Ananth, LaShun L Horn, Koen Andries, Pooran Chand, Pravin L. Kotian, Ali Dehghani, Yahya A. El-Kattan, T. Lin et al. · 2001 · Antimicrobial Agents and Chemotherapy
  80. Design, Synthesis, and in Vitro Biological Evaluation of 1H-1,2,3-Triazole-4-carboxamide Derivatives as New Anti-influenza A Agents Targeting Virus Nucleoprotein
    Huimin Cheng, Junting Wan, Meng‐I Lin, Yingxue Liu, Xiaoyun Lu, Jinsong Liu, Yong Xu, Jianxin Chen, Zhengchao Tu, Yih‐Shyun E. Cheng et al. · 2012 · Journal of Medicinal Chemistry
  81. The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: a potent influenza virus sialidase inhibitor
    Mark von Itzstein, Wen-Yang Wu, Betty Jin · 1994 · Carbohydrate Research
  82. Characterization of Influenza A/HongKong/156/97 (H5N1) Virus in a Mouse Model and Protective Effect of Zanamivir on H5N1 Infection in Mice
    Larisa V. Gubareva, Jonathan A. McCullers, Richard C. Bethell, Robert G. Webster · 1998 · The Journal of Infectious Diseases
  83. The impact of GPCR structures on pharmacology and structure‐based drug design
    Miles Congreve, Fiona H. Marshall · 2009 · British Journal of Pharmacology
  84. High‐Yielding Synthesis of the Anti‐Influenza Neuraminidase Inhibitor (−)‐Oseltamivir by Two “One‐Pot” Sequences
    Hayato Ishikawa, Takaki Suzuki, Hideo Orita, Tadafumi Uchimaru, Yujiro Hayashi · 2010 · Chemistry - A European Journal
  85. Emerging themes in medicinal glycoscience
    Kathryn M. Koeller, Chi‐Huey Wong · 2000 · Nature Biotechnology
  86. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase)
    David Ryan, John R. Ticehurst, M H Dempsey, Charles R. Penn · 1994 · Antimicrobial Agents and Chemotherapy
  87. Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice
    Natalia A. Ilyushina, Erich Hoffmann, Rachelle Salomon, Robert G. Webster, Elena A. Govorkova · 2007 · Antiviral Therapy
  88. Drugs in Development for Influenza
    David A. Boltz, Jerry R. Aldridge, Robert G. Webster, Elena A. Govorkova · 2010 · Drugs
  89. New, Azide-Free Transformation of Epoxides into 1,2-Diamino Compounds: Synthesis of the Anti-Influenza Neuraminidase Inhibitor Oseltamivir Phosphate (Tamiflu)
    Martin Karpf, René Trussardi · 2001 · The Journal of Organic Chemistry
  90. Characterization of Human Influenza Virus Variants Selected In Vitro in the Presence of the Neuraminidase Inhibitor GS 4071
    Chun Y. Tai, Paul A. Escarpe, Robert W. Sidwell, Matthew A. Williams, Willard Lew, Huiwei Wu, Choung U. Kim, Dirk B. Mendel · 1998 · Antimicrobial Agents and Chemotherapy
  91. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease
    Anne Moscona · 2005 · Journal of Clinical Investigation
  92. Structural glycobiology: A game of snakes and ladders
    Mari L. DeMarco, Robert J. Woods · 2008 · Glycobiology
  93. A good ligand is hard to find: Automated docking methods
    Jeffrey M. Blaney, J. Scott Dixon · 1993 · Perspectives in Drug Discovery and Design
  94. Molecular strategies to inhibit the replication of RNA viruses
    Pieter Leyssen, Erik De Clercq, Johan H. Neyts · 2008 · Antiviral Research
  95. Structural basis of sialyltransferase activity in trypanosomal sialidases
    Buschiazzo, Alejandro, Tavares, Gisele A., Campetella, Oscar, Spinelli, Silvia, Cremona, Marfa L., París, Gastón, Fernanda Amaya, Maria, Frasch, Alberto C.C., Alzari, Pedro M. · 2000 · The EMBO Journal
  96. Gangliosides as influenza virus receptors. Variation of influenza viruses and their recognition of the receptor sialo-sugar chains
    Yasuo Suzuki · 1994 · Progress in Lipid Research
  97. Stereoselective reactions of nitro compounds in the synthesis of natural compound analogs and active pharmaceutical ingredients
    Alexey Yu. Sukhorukov, Anna A. Sukhanova, Sergei Grigorievich Zlotin · 2016 · Tetrahedron
  98. Molecular Docking Screens Using Comparative Models of Proteins
    Fan, Hao, Irwin, John J., Webb, Benjamin M., Klebe, Gerhard, Shoichet, Brian K., Sali, Andrej · 2009 · Journal of Chemical Information and Modeling
  99. Dissecting conformational contributions to glycosidase catalysis and inhibition
    Gaetano Speciale, Andrew J. Thompson, G.J. Davies, Spencer John Williams · 2014 · Current Opinion in Structural Biology
  100. Characterizing Loop Dynamics and Ligand Recognition in Human- and Avian-Type Influenza Neuraminidases via Generalized Born Molecular Dynamics and End-Point Free Energy Calculations
    Rommie E. Amaro, Xiaolin Cheng, Ivaylo N. Ivanov, Dong Xu, James Andrew McCammon · 2009 · Journal of the American Chemical Society